Protective effect of metformin in an aberrant crypt foci model induced by 1, 2‐dimethylhydrazine: Modulation of oxidative stress and inflammatory process. Issue 3 (27th September 2016)

• Record Type: Journal Article
• Authors: Bordini, Heloíza Paranzini; Kremer, Jean Lucas; Fagundes, Tatiane Renata; Melo, Gabriella Pasqual; Conchon‐Costa, Ivete; da Silva, Suelen Santos; Cecchini, Alessandra Lourenço; Panis, Carolina; Luiz, Rodrigo Cabral
• Is Part Of: Molecular carcinogenesis. Volume 56:Issue 3(2017)
• Page Start: 913
• Page End: 922
• Publication Date: 2016-09-27
• Subjects: colorectal cancer -- metformin -- 1, 2‐dimethylhydrazine -- aberrant crypt foci -- prevention; Carcinogenesis -- Molecular aspects -- Periodicals; 616.994071
• DOI: 10.1002/mc.22545
• Languages: English
• ISSNs: 0899-1987

Abstract

Abstract : Colorectal Cancer (CRC) is the third most frequent type of cancer worldwide. In the past few years, studies have revealed a protective effect of metformin (MET—an anti‐hyperglycemic drug, used to treat type 2 diabetes), against CRC. The protective effect of MET has been associated with AMPK activation (and mTOR inhibition), resulting in suppressed protein synthesis, and reduced cell proliferation in malignant transformed cells. To elucidate new mechanisms for the protective effect of metformin, we evaluated the oxidative stress and inflammatory process modulation, since these processes are strictly involved in colorectal carcinogenesis. The present study evaluated the protective effect of MET in a CRC model induced by 1, 2‐dimethylhydrazine (DMH) in Balb/c female mice. The simultaneous/continuous treatment (administration of MET and DMH simultaneously), revealed protective activity of MET, preventing the formation of aberrant crypt foci (ACF) in 71.4% at distal colon sections, and was able to restore basal labeling of apoptosis. Treatment with MET also reduced the inflammatory process induced by DMH, resulting in of the reduction of oxidative stress and nitric oxide related parameters. © 2016 Wiley Periodicals, Inc.